Effect of COVID-19 on Bronchiectasis Exacerbation Rates: A Retrospective US Insurance Claims Study.
Annika ÅstrandSteven J KiddleRohith Siva Ganesh MudedlaSanchita PorwalKaushik ChafekarShubh AgrawalCarlos SeminarioJames D ChalmersIoannis PsallidasPublished in: Annals of the American Thoracic Society (2023)
In a U.S. population-based study of patients with ICD codes for bronchiectasis, the rate of exacerbations during year 1 of the COVID-19 pandemic was reduced compared with the 2-year time period preceding the pandemic. Primary Source of Funding (if any): AstraZeneca (Cambridge, UK).